Business
Vortex Initiates Clinical Research Studies
Vortex Initiates Clinical Research Studies.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 0115G NetScientific PLC 24 May 2017 \n\n \n \nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \nVortex Biosciences Announces Initiation of Clinical Research Studies with UCLA in Non-Small Cell Lung Cancer Patients\n \n \nLondon, UK - May 24th 2017 - NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company, Vortex Biosciences (\"Vortex\"), yesterday announced that it has initiated two clinical research studies with UCLA in patients with Non-Small Cell Lung Cancer (NSCLC). These studies will provide proof of principle that well understood biomarkers currently utilised in tumor biopsies to support treatment decisions can be similarly utilized in circulating tumour cells (CTCs).\nCommenting on the news, François R. Martelet, Chief Executive Officer of NetScientific and Chairman of Vortex Biosciences, said: \"Vortex's mission is to be the world-leader in CTC technology, enabling physicians to make accurate, real-time decisions when diagnosing, treating and monitoring patients with cancer. These two proof of principle clinical research studies, In collaboration with UCLA, are a vital step in clinically validating and thus commercialising the Company's first product, the VTX-1 system. Vortex is currently working with researchers and clinicians in the US to build on the positive data already seen, to accelerate commercialisation in the future.\"\n \nThe full text of the announcement is below:\n \nVortex Biosciences Initiates Clinical Research Studies with UCLA in Non-Small Cell Lung Cancer Patients\n \nClinical Research Studies Intended to Identify Utility of Characterizing Circulating Tumor Cells for Key Companion Diagnostics\n \nMENLO PARK, CA, May 23, 2017 - Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced that they have initiated 2 clinical research studies with UCLA in Non-Small Cell Lung Cancer (NSCLC) patients. These studies are intended to provide proof of principle that well understood biomarkers currently utilized in tumor biopsies to support treatment decisions can be similarly utilized in CTCs. \n \nClinicians continue to rely on invasive tissue biopsies as a means to assess a patient's disease and prescribe appro...